Cargando…
Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies
Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have deve...
Autores principales: | Kobayashi, Eiji, Kamihara, Yusuke, Arai, Miho, Wada, Akinori, Kikuchi, Shohei, Hatano, Ryo, Iwao, Noriaki, Susukida, Takeshi, Ozawa, Tatsuhiko, Adachi, Yuichi, Kishi, Hiroyuki, Dang, Nam H., Yamada, Taketo, Hayakawa, Yoshihiro, Morimoto, Chikao, Sato, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453178/ https://www.ncbi.nlm.nih.gov/pubmed/37626869 http://dx.doi.org/10.3390/cells12162059 |
Ejemplares similares
-
DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies
por: Kikuchi, Shohei, et al.
Publicado: (2023) -
Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect
por: Yamada, Kohji, et al.
Publicado: (2009) -
CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma Cells
por: Okamoto, Toshihiro, et al.
Publicado: (2014) -
Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014) -
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
por: Nishida, Hiroko, et al.
Publicado: (2018)